

Home oxygen therapy versus home mechanical ventilation for chronic obstructive pulmonary disease

| | | |
|--|---|---|
| Submission date 31/03/2010 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 31/03/2010 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 05/06/2017 | Condition category Respiratory | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Chronic obstructive pulmonary disease (COPD) is the name for a collection of lung diseases usually caused by smoking. When symptoms become particularly bad this is called an exacerbation. Some exacerbations of COPD can be very severe and patients need support from breathing machines (ventilators) in addition to oxygen therapy. Previous studies have examined whether the use of a ventilator at home, termed home mechanical ventilation, could help improve people's breathing and reduce the need for readmission to hospital, but these studies have not been able to demonstrate a benefit. This is thought to be due to the poor design of the studies rather than failure of the ventilator itself. This study is a UK-wide study to investigate if home mechanical ventilation in addition to home oxygen therapy is better than home oxygen therapy on its own.

Who can participate?

Patients aged 18 or older who have had a life-threatening COPD exacerbation at least 2 weeks ago

What does the study involve?

Participants are randomly allocated to receive home oxygen therapy with or without home mechanical ventilation. They are followed up for 12 months to see if patients who received home mechanical ventilation have fewer hospital admissions.

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

St Thomas's Hospital (UK)

When is the study starting and how long is it expected to run for?

October 2009 to June 2016

Who is funding the study?

1. Guy's and St. Thomas' Charity (UK)
2. Respironics, Inc. (USA)
3. ResMed Ltd (Australia)

Who is the main contact?

Dr Patrick Murphy

Contact information

Type(s)

Scientific

Contact name

Dr Patrick Murphy

Contact details

St Thomas's Hospital
249 Westminster Bridge Road
London
United Kingdom
SE1 7EH

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00990132

Protocol serial number

8059

Study information

Scientific Title

Randomised controlled trial of home mechanical ventilation in hypercapnic chronic obstructive pulmonary disease patients post acute hypercapnic exacerbation

Acronym

HOT HMV in COPD

Study objectives

The trial is designed to test the hypothesis that the use of home non-invasive ventilation (NIV) in persistently hypercapnic chronic obstructive pulmonary disease (COPD) patients following an acute hypercapnic exacerbation of COPD reduces hospital admissions and improves survival.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Study design

Randomised interventional multicentre treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Respiratory; Subtopic: Respiratory (all Subtopics); Disease: Respiratory

Interventions

1. Domiciliary non-invasive ventilation (HMV)
2. Home oxygen therapy (HOT)

Follow up length: 12 month(s)

Study entry: Single randomisation only

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Admission-free survival up to 12 months

Key secondary outcome(s)

Measured at 6 weeks, 3 months, 6 months, 12 months:

1. Daily activity - actigraphy
2. Exercise tolerance
3. Pulmonary mechanics
4. Respiratory muscle strength
5. Sleep quality - actigraphy

Completion date

30/06/2016

Eligibility

Key inclusion criteria

1. Acute hypercapnic exacerbation of COPD at least 2 weeks previously
2. In patient admission with acute hypercapnic respiratory failure
3. Smoking greater than 20 pack year history
4. Forced expiratory volume in one second (FEV1) less than 50%
5. FEV1/forced vital capacity (FVC) less than 60%
6. Chronic hypercapnia (PaCO₂ greater than 7 kPa)

7. Chronic hypoxia PaO₂ less than 7.3 kPa or less than 8 kPa with secondary polycythaemia, pulmonary hypertension, peripheral oedema or significant nocturnal hypoxia (SpO₂ less than 90% for greater than 30% sleep time)
8. Aged 18 years or older, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Unable to wean off NIV prior to discharge (persistent hypercapnic respiratory failure with pH less than 7.30)
2. Post extubation or decanulation
3. Body mass index (BMI) greater than 35 kg/m²
4. Primary diagnosis of restrictive lung disease causing hypercapnia
5. Development of worsening hypercapnic respiratory failure with acidosis during initiation of oxygen therapy (ABG - pH less than 7.30 taken 2 - 4 hours after waking)
6. Unable to tolerate NIV (if given) during acute illness
7. Unstable coronary artery syndrome
8. Renal replacement therapy
9. Inability to consent/comply with trial protocol (as determined by site PI)
10. Aged less than 18 years
11. Pregnant

Date of first enrolment

01/02/2010

Date of final enrolment

30/06/2016

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

St Thomas's Hospital

London

United Kingdom

SE1 7EH

Sponsor information

Organisation

Guy's and St. Thomas' NHS Foundation Trust (UK)

ROR

<https://ror.org/00j161312>

Funder(s)

Funder type

Industry

Funder Name

Guy's and St. Thomas' Charity (UK)

Alternative Name(s)

Guy's and St Thomas' Charity, Guy's and St Thomas' Foundation, GSTTFoundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

Respironics, Inc. (USA)

Funder Name

ResMed Ltd (Australia)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to institution policy.

IPD sharing plan summary

Not expected to be made available

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 06/06/2017 | | Yes | No |